Enrollment currently scheduled to begin in Q1 2026 M107 is the first potential disease-modifying drug for the treatment of gastroparesis M107’s mechanism of action has been shown to shift ...

RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the Company has ...

Chong Kun Dang said on the 27th that its global partner, Aclipse Therapeutics, signed an agreement with the Mayo Clinic for a phase 2 clinical trial of the gastroparesis treatment candidate "M107 ...

It's all about that van life for Emily Bruns and Sofia Mimendi. A few years ago, the two were new friends training for a marathon. To pass the time during their long runs, the pair would toss out ...

Are you looking to hit the road this spring? Here’s an idea for you—leave the winter blues behind and head out in an Aclipse Campervan. Aclipse is like an Airbnb for van rentals. Based in Cincinnati, ...

Company to advance M107 into Phase 2 clinical development in gastroparesis based on feedback from Pre-IND meeting with FDA RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics, and its subsidiary, ...

M102 is a disease-modifying drug candidate for motor neuron disease (MND) that was discovered by Sheffield scientists in 2013 University of Sheffield partnership with Aclipse Therapeutics awarded a £1 ...

KING OF PRUSSIA, Pa., November 17, 2025--(BUSINESS WIRE)--Aclipse Therapeutics LLC ("Aclipse" or "the Company") today announced that it has entered into a clinical collaboration and Know-How Agreement ...

Chong Kun Dang announced on the 27th that its global license partner for the novel diabetes drug lobeglitazone (brand name Duvie), Aclipse Therapeutics, has signed an agreement with the Mayo Clinic in ...